FLAIR: Week 124 Results of Long-Acting Injectable Cabotegravir + Rilpivirine

July 18-21, 2021; Virtual
At Week 124, 80% of patients still demonstrated virologic suppression on monthly injectable cabotegravir + rilpivirine, with no new safety signals since the Week 96 analysis.
Format: Microsoft PowerPoint (.ppt)
File Size: 257 KB
Released: July 21, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Dr Neha Pandit discusses barriers and solutions to PrEP uptake in key patient populations in this commentary from Clinical Care Options (CCO)

person default Neha Pandit, PharmD, AAHIVP, BCPS Released: December 2, 2022

Dr Monica Gandhi discusses key advances in HIV treatment over the past year, from Clinical Care Options (CCO)

Monica Gandhi, MD, MPH Released: December 2, 2022

A patient advocate discusses the importance of community-led HIV treatment and prevention, from Clinical Care Options (CCO)

person default Rena Janamnuaysook, MBA Released: December 2, 2022

Clinical Care Options (CCO) expert analysis of new data from IDWeek and HIV Glasgow 2022, provided by expert HIV faculty

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: November 30, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings